期刊文献+

Ang-2、MMP-2在乳腺癌中的表达及意义 被引量:1

The significance of Ang-2 and MMP-2 expressions in breast cancer
下载PDF
导出
摘要 目的探讨Ang-2、MMP-2表达与乳腺癌临床病理特征的关系,分析二者表达的相关性。方法采用免疫组化SABC法检测46例乳腺浸润性导管癌和10例乳腺纤维腺瘤组织中Ang-2、MMP-2的表达水平。结果46例乳腺癌组织中Ang-2、MMP-2表达阳性率分别为56.5%、73.9%,高于乳腺纤维腺瘤。Ang-2、MMP-2的表达水平与乳腺癌组织学分级显著相关;腋窝淋巴结转移组Ang-2、MMP-2表达阳性率高于无转移组。Ang-2、MMP-2的表达相互之间显著相关。结论乳腺癌组织中Ang-2、MMP-2表达上调,在乳腺癌发生、发展过程中具有重要作用。Ang-2、MMP-2协同刺激乳腺癌血管生成,可能是促进乳腺癌发生转移的重要机制。Ang-2可能成为判断乳腺癌预后的重要指标。 Objective: To investigate the expressions of Ang-2 and MMP-2 in breast cancer and its correlations with clinicopathological characteristics, and to analyze the association of Ang-2 and MMP-2 in breast cancer. Methods : Expressions of Ang-2 and MMP-2 in 46 breast invasive ductal carcinoma and 10 breast fibroadenoma spicemens were detected by immunohistochemical method (SABC). Results: Ang-2 and MMP-2 positive expression rates were 56.5% and 73.9% in 46 breast carcinomas respectively, which were significantly higher than those in breast fibroadenomas. In high histological grade diseases Ang-2 and MMP-2 positive rates were significantly higher than those in low grade diseases. Ang-2 and MMP- 2 positive expressions were associated with axillary lymph node metastases. Significant correlations were found between Ang-2 and MMP-2 expressions. Conclusion: Ang-2 and MMP-2 over-expressions in breast caicinoma are significantly corre- lated with occurrence, development of breast cancer. Ang-2, MMP-2 cooperate in promoting the vascular growth of breast cancer. Ang-2 might serve as a valuable prognostic indicator in breast cancer.
出处 《泰山医学院学报》 CAS 2009年第6期417-419,共3页 Journal of Taishan Medical College
关键词 血管生成素 基质金属蛋白酶 乳腺肿瘤 免疫组化 angiopoietin matrix metalloproteinase breast cancer immunohistochemistry
  • 相关文献

参考文献15

  • 1Stoeltzing O,Ahmad SA,Liu W,et al.Angiopoietin-1 inhibits vascular permeability,angiogenesis,and growth of hepatic colon cancer tumors[J].Cancer Res,2003,63 (12):3370-3377.
  • 2Kohlberger P,Edwards L,Hacker NF.Microinvasive squamous cell carcinoma of the cervix:immunohistocbemically detected prognostic factors in a case with poor clinical outcome[J].Gynecol Oncol,2003,90(2):443-445.
  • 3Tsutsui S,Inoue H,Yasuda K,et al.Angiopoietin 2 expression in invasive ductal carcinoma of the breast:its relationship to the VEGF expression and microvessel density[J].Breast Cancer Res Treat,2006,98(3):261-266.
  • 4Krikun G,Schatz F,Finlay T,et al.Expression of angiopoietin-2 by human endometrial endothelial cells:regulation by hypexia and inflammation[J].Biochem Biophys Res Commun,2000,275 (1):159-163.
  • 5Wang J,Wu K,Zhang D,et al.Expressions and clinical significances of angiopoietin-1,-2 and Tie2 in human gastric cancer[J].Biochem Biophys Bes Commun,2005,337(1):386-393.
  • 6Ahmad SA,Liu W,Jung YD,et al.Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma.A possible mechanism for the initiation of angiogenesis[J].Cancer,2001,92(5):1138-1143.
  • 7Sfiligoi C,De Luca A,Cascone I,et al.Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival[J].Int J Cancer,2003,103(4):466-474.
  • 8Jones JL,Glynn P,Walker RA,et al.Expression of MMP-2 and MMP-9,their inhibitors,and the activator MT1-MMP in primary breast carcinomas[J].J Pathol,1999,189 (2):161-168.
  • 9Etoh T,Inoue H,Tanaka S,et al.Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma:possible in vivo regulation via induction of proteases[J].Cancer Res,2001,61 (5):2145-2153.
  • 10Hu B,Jarzynka M J,Guo P,et al.Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the αvβ1 integrin and focal adhesion kinase signaling pathway[J].Cancer Res,2006,66(2):775-783.

同被引文献16

  • 1李治,帅晓明,黄韬.c-erbB-2、MMP-2、MMP-9表达水平与乳腺癌恶性程度的相关性[J].华中科技大学学报(医学版),2005,34(6):757-759. 被引量:2
  • 2Szabo KA, Singh G.Modulation of monocyte matrix metallopro-teinase-2 by breast adenocarcinoma cells [J]. Breast Cancer Res, 2005, 7 (5): 661-668.
  • 3Jones JL, Glynn P, Walker RA, et al. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1 · MMP in primary breast carcinomas[J]. J Pathol, 1999, 189 (2): 161-168.
  • 4Nakopoulou L, Katsarou S, Giannopoulou I, et al. Corr-elation of tissue inhibitor of metaUoproteinase-2 with proliferative activity and patients' survival in breast cancer [J]. Mod Pathol, 2002, 15 (1): 26-34.
  • 5Li HC, Can DC, Liu Y. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph nodenega- tire breast carci-noma [J]. Breast Cancer Res Treat, 2004, 88 (1) : 75-77.
  • 6Mrena J, Wiksten JP, Nordling S, et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer [J]. J Clin Pathol, 2006, 59 (6): 618-623.
  • 7Kubben FJ, Sier CF, Van Duijn W, et al. Matrix metallopro- teinase-2 is a consistent prognostic factor in gastric cancer[J]. Br J Cancer, 2006, 94 (7): 1035-1040.
  • 8Xie Z, Yuan H, Yin Y, et al. 3-Phosphoinositide-dependent protein Kinasn-1 (PDKI) promotes invasion and activation of matrix metalloproteinases[J]. BMC Cancer, 2006, 6 (1): 77-81.
  • 9Shah FD, Shukla SN, Shah PM, et al. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer[J]. Indian J Cancer. 2009, 46 (3): 194-202.
  • 10Leppa S, Saarto T, Vehrnanen L, et al. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node2positive breast carcinoma [J]. Clin Cancer Res, 2004, 10 (3) : 1057-1063.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部